tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Aug 14;10(8):1315.
doi: 10.3390/vaccines10081315.
Kinetic of the Antibody Response Following AddaVax-Adjuvanted Immunization with Recombinant Influenza Antigens
Ted M Ross[SUP] 1 2 [/SUP], Naveen Gokanapudi[SUP] 1 [/SUP], Pan Ge[SUP] 1 [/SUP], Hua Shi[SUP] 1 [/SUP], Robert A Richardson[SUP] 1 [/SUP], Spencer R Pierce[SUP] 1 [/SUP], Pedro Sanchez[SUP] 1 [/SUP], Subhan Ullah[SUP] 1 [/SUP], Eliana De Luca[SUP] 1 2 [/SUP], Giuseppe A Sautto[SUP] 1 [/SUP]
Affiliations
Abstract
Notwithstanding the current SARS-CoV-2 pandemic, influenza virus infection still represents a global health concern in terms of hospitalizations and possible pandemic threats. The objective of next-generation influenza vaccines is not only to increase the breadth of response but also to improve the elicitation of an effective and robust immune response, especially in high-risk populations. To achieve this second objective, the administration of adjuvanted influenza vaccines has been considered. In this regard, the monitoring and characterization of the antibody response associated with the administration of adjuvanted vaccines has been evaluated in this study in order to shed light on the kinetic, magnitude and subclass usage of antibody secreting cells (ASCs) as well as of circulating antigen-specific serum antibodies. Specifically, we utilized the DBA/2J mouse model to assess the kinetic, magnitude and IgG subclass usage of the antibody response following an intramuscular (IM) or intraperitoneal (IP) immunization regimen with AddaVax-adjuvanted bivalent H1N1 and H3N2 computationally optimized broadly reactive antigen (COBRA) influenza recombinant hemagglutinins (rHAs). While the serological evaluation revealed a homogeneous kinetic of the antibody response, the detection of the ASCs through a FluoroSpot platform revealed a different magnitude, subclass usage and kinetic of the antigen-specific IgG secreting cells peaking at day 5 and day 9 following the IP and IM immunization, respectively.
Keywords: AddaVax; IgG subclasses; adjuvant; antibody; antibody-secreting cells (ASCs); computationally optimized broadly reactive antigens (COBRA); hemagglutinin (HA); influenza vaccine; influenza virus.
. 2022 Aug 14;10(8):1315.
doi: 10.3390/vaccines10081315.
Kinetic of the Antibody Response Following AddaVax-Adjuvanted Immunization with Recombinant Influenza Antigens
Ted M Ross[SUP] 1 2 [/SUP], Naveen Gokanapudi[SUP] 1 [/SUP], Pan Ge[SUP] 1 [/SUP], Hua Shi[SUP] 1 [/SUP], Robert A Richardson[SUP] 1 [/SUP], Spencer R Pierce[SUP] 1 [/SUP], Pedro Sanchez[SUP] 1 [/SUP], Subhan Ullah[SUP] 1 [/SUP], Eliana De Luca[SUP] 1 2 [/SUP], Giuseppe A Sautto[SUP] 1 [/SUP]
Affiliations
- PMID: 36016202
- DOI: 10.3390/vaccines10081315
Abstract
Notwithstanding the current SARS-CoV-2 pandemic, influenza virus infection still represents a global health concern in terms of hospitalizations and possible pandemic threats. The objective of next-generation influenza vaccines is not only to increase the breadth of response but also to improve the elicitation of an effective and robust immune response, especially in high-risk populations. To achieve this second objective, the administration of adjuvanted influenza vaccines has been considered. In this regard, the monitoring and characterization of the antibody response associated with the administration of adjuvanted vaccines has been evaluated in this study in order to shed light on the kinetic, magnitude and subclass usage of antibody secreting cells (ASCs) as well as of circulating antigen-specific serum antibodies. Specifically, we utilized the DBA/2J mouse model to assess the kinetic, magnitude and IgG subclass usage of the antibody response following an intramuscular (IM) or intraperitoneal (IP) immunization regimen with AddaVax-adjuvanted bivalent H1N1 and H3N2 computationally optimized broadly reactive antigen (COBRA) influenza recombinant hemagglutinins (rHAs). While the serological evaluation revealed a homogeneous kinetic of the antibody response, the detection of the ASCs through a FluoroSpot platform revealed a different magnitude, subclass usage and kinetic of the antigen-specific IgG secreting cells peaking at day 5 and day 9 following the IP and IM immunization, respectively.
Keywords: AddaVax; IgG subclasses; adjuvant; antibody; antibody-secreting cells (ASCs); computationally optimized broadly reactive antigens (COBRA); hemagglutinin (HA); influenza vaccine; influenza virus.